247 related articles for article (PubMed ID: 20172070)
21. Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy.
Lim JI; Glassman AR; Aiello LP; Chakravarthy U; Flaxel CJ; Spaide RF;
Ophthalmology; 2014 May; 121(5):1073-8. PubMed ID: 24439758
[TBL] [Abstract][Full Text] [Related]
22. Angiographic and Tomographic Prognostic Factors of Chronic Central Serous Chorioretinopathy Treated with Half-Dose Photodynamic Therapy.
Chung CY; Chan YY; Li KKW
Ophthalmologica; 2018; 240(1):37-44. PubMed ID: 29566395
[TBL] [Abstract][Full Text] [Related]
23. Comparison between the outcomes of fluorescein angiography-guided and indocyanine green angiography-guided half-time photodynamic therapy for central serous chorioretinopathy.
Hayashida M; Miki A; Honda S; Nakamura M
Photodiagnosis Photodyn Ther; 2020 Sep; 31():101955. PubMed ID: 32818640
[TBL] [Abstract][Full Text] [Related]
24. Functional retinal changes measured by microperimetry in standard-fluence vs low-fluence photodynamic therapy in chronic central serous chorioretinopathy.
Reibaldi M; Boscia F; Avitabile T; Uva MG; Russo A; Zagari M; Occhipinti F; Russo V; Reibaldi A; Longo A
Am J Ophthalmol; 2011 Jun; 151(6):953-960.e2. PubMed ID: 21457929
[TBL] [Abstract][Full Text] [Related]
25. INSTRUMENTAL DIFFERENCE IN ASSESSING CHOROIDAL HYPERPERMEABILITY AND PHOTODYNAMIC THERAPY IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
Lee SM; Kwon HJ; Park SW; Lee JE; Byon IS
Retina; 2019 Jul; 39(7):1361-1369. PubMed ID: 29554076
[TBL] [Abstract][Full Text] [Related]
26. Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy.
Smretschnig E; Hagen S; Glittenberg C; Ristl R; Krebs I; Binder S; Ansari-Shahrezaei S
Eye (Lond); 2016 Jun; 30(6):805-11. PubMed ID: 26965012
[TBL] [Abstract][Full Text] [Related]
27. A Multicenter Study on the Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy.
Lai FH; Ng DS; Bakthavatsalam M; Chan VC; Young AL; Luk FO; Tsang CW; Brelén ME
Am J Ophthalmol; 2016 Oct; 170():91-99. PubMed ID: 27519561
[TBL] [Abstract][Full Text] [Related]
28. Half-fluence photodynamic therapy in acute central serous chorioretinopathy.
Smretschnig E; Ansari-Shahrezaei S; Moussa S; Glittenberg C; Krebs I; Binder S
Retina; 2012; 32(10):2014-9. PubMed ID: 22466482
[TBL] [Abstract][Full Text] [Related]
29. RESPONSE OF CHOROIDAL ABNORMALITIES TO PHOTODYNAMIC THERAPY VERSUS MICROPULSE LASER IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: Place Trial Report No. 4.
van Rijssen TJ; Hahn LC; van Dijk EHC; Tsonaka R; Scholz P; Breukink MB; Blanco-Garavito R; Souied EH; Keunen JEE; MacLaren RE; Querques G; Fauser S; Downes SM; Hoyng CB; Boon CJF
Retina; 2021 Oct; 41(10):2122-2131. PubMed ID: 34543244
[TBL] [Abstract][Full Text] [Related]
30. A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial.
Zhao M; Zhang F; Chen Y; Dai H; Qu J; Dong C; Kang X; Liu Y; Yang L; Li Y; Zhou P; Pan CT; Zhang L; Liu P; Zhou H; Jiao X; Xiong Y; Tian R; Lu Y; Yu X; Li X
JAMA Ophthalmol; 2015 Mar; 133(3):333-40. PubMed ID: 25555191
[TBL] [Abstract][Full Text] [Related]
31. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial.
Chan WM; Lai TY; Lai RY; Liu DT; Lam DS
Ophthalmology; 2008 Oct; 115(10):1756-65. PubMed ID: 18538401
[TBL] [Abstract][Full Text] [Related]
32. OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY-GUIDED PHOTODYNAMIC THERAPY FOR ACUTE CENTRAL SEROUS CHORIORETINOPATHY.
Hu J; Qu J; Li M; Sun G; Piao Z; Liang Z; Yao Y; Sadda S; Zhao M
Retina; 2021 Jan; 41(1):189-198. PubMed ID: 32343102
[TBL] [Abstract][Full Text] [Related]
33. Detection of morphologic alterations by spectral-domain optical coherence tomography before and after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy.
Shinojima A; Kawamura A; Mori R; Fujita K; Yuzawa M
Retina; 2011 Oct; 31(9):1912-20. PubMed ID: 21952105
[TBL] [Abstract][Full Text] [Related]
34. Very minimal fluence photodynamic therapy for chronic central serous chorioretinopathy.
Butler AL; Fung AT; Merkur AB; Albiani DA; Forooghian F
Can J Ophthalmol; 2012 Feb; 47(1):42-4. PubMed ID: 22333850
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of photodynamic therapy in steroid-associated chronic central serous chorioretinopathy: a case-control study.
Breukink MB; Mohabati D; van Dijk EH; den Hollander AI; de Jong EK; Dijkman G; Keunen JE; Hoyng CB; Boon CJ
Acta Ophthalmol; 2016 Sep; 94(6):565-72. PubMed ID: 27149889
[TBL] [Abstract][Full Text] [Related]
36. Half-dose photodynamic therapy targeting the leakage point on the fluorescein angiography in acute central serous chorioretinopathy: a pilot study.
Kim KS; Lee WK; Lee SB
Am J Ophthalmol; 2014 Feb; 157(2):366-373.e1. PubMed ID: 24184226
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Focal and Conventional Verteporfin Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
Noh SR; Kang MS; Kim K; Kim ES; Yu SY
Korean J Ophthalmol; 2019 Dec; 33(6):506-513. PubMed ID: 31833247
[TBL] [Abstract][Full Text] [Related]
38. Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).
Lai TY; Wong RL; Chan WM
Trans Am Ophthalmol Soc; 2015; 113():T8. PubMed ID: 26755855
[TBL] [Abstract][Full Text] [Related]
39. Genetic factors associated with treatment response to reduced-fluence photodynamic therapy for chronic central serous chorioretinopathy.
Hayashida M; Miki A; Nakai S; Matsumiya W; Imai H; Kusuhara S; Honda S; Nakamura M
Mol Vis; 2020; 26():505-509. PubMed ID: 32774081
[TBL] [Abstract][Full Text] [Related]
40. The effect of photodynamic therapy on macular sensitivity in eyes with acute central serous chorioretinopathy.
Hagen S; Ansari-Shahrezaei S; Smretschnig E; Glittenberg C; Krebs I; Graf A; Binder S
Graefes Arch Clin Exp Ophthalmol; 2013 Apr; 251(4):1081-9. PubMed ID: 22926253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
